A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
RO7812653
DRUG:
Placebo
Sponsor
Hoffmann-La Roche